文献速递糖尿病

糖尿病患者使用GLP-1受体激动剂与SGLT2抑制剂的主要不良心血管及肢体事件比较

Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors.
PubMed 文献 · Diabetologia · 2022-08-09

基于台湾全民健康保险研究数据库的回顾性队列研究,纳入379,256例2016年5月1日至2019年12月31日期间起始GLP1RA或SGLT2i治疗的糖尿病患者,经1:4倾向评分匹配后分析287,091例。结果显示GLP1RA组主要不良肢体事件发生率显著低于SGLT2i组(3.6 vs 4.5事件/1000人年;亚分布HR 0.80;95%CI 0.67, 0.96),在糖尿病周围神经病变患者中尤为明显。

要点

  • GLP1RA组主要不良肢体事件发生率显著低于SGLT2i组(3.6 vs 4.5事件/1000人年;亚分布HR 0.80;95%CI 0.67, 0.96)。
  • MALE风险降低主要归因于危重肢体缺血发生率降低。
  • 在糖尿病周围神经病变患者中,GLP1RA与SGLT2i的MALE风险关联差异显著(亚分布HR 0.66 vs 1.11;交互作用P=0.006)。

核心结论

  • 在糖尿病患者中,与SGLT2i相比,起始GLP1RA治疗后2年内与主要不良肢体事件风险显著降低相关,尤其在糖尿病神经病变患者中。

研究设计与样本

  • 回顾性队列研究,数据来自台湾全民健康保险研究数据库,共识别379,256例2016年5月1日至2019年12月31日期间起始GLP1RA或SGLT2i治疗的糖尿病患者,经1:4倾向评分匹配后,287,091例纳入分析(SGLT2i组81,152例,GLP1RA组20,288例)。

主要发现

  • GLP1RA组主要不良肢体事件发生率显著低于SGLT2i组(3.6 vs 4.5事件/1000人年;亚分布HR 0.80;95%CI 0.67, 0.96),主要归因于危重肢体缺血发生率降低。
  • 在糖尿病周围神经病变患者中,GLP1RA与SGLT2i的MALE风险关联差异显著(亚分布HR 0.66 vs 1.11;交互作用P=0.006)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: This study aimed to assess the real-world outcomes of people with diabetes mellitus treated with glucagon-like peptide-1 receptor agonists (GLP1RAs) compared with those treated with sodium-glucose cotransporter 2 inhibitors (SGLT2is) in terms of major adverse cardiovascular and limb events. Peripheral artery disease is a common cause of morbidity in people with diabetes. Previous cardiovascular outcome trials have demonstrated the benefits of GLP1RAs and SGLT2is for reducing various cardiovascular events, but the safety and efficacy of these drugs on limb outcomes remain subject to debate and ambiguity. METHODS: A retrospective cohort study was conducted in which data were collected from the Taiwan National Health Insurance Research Database. In total, 379,256 individuals with diabetes receiving either GLP1RA or SGLT2i with treatment initiated between 1 May 2016 and 31 December 2019 were identified. The primary outcome was major adverse limb events (MALE), defined as the composite of newly diagnosed critical limb ischaemia, percutaneous transluminal angioplasty or peripheral bypass for peripheral artery disease, and non-traumatic amputation. The secondary outcome was major adverse cardiac events, which was a composite of cardiovascular death, non-fatal myocardial infarction and non-fatal ischaemic stroke. Other examined outcomes included death from any cause and hospitalisation for heart failure. Propensity score matching was performed at a 1:4 ratio between the GLP1RA and SGLT2i groups to mitigate possible selection bias. RESULTS: A total of 287,091 patients were eligible for analysis, with 81,152 patients treated with SGLT2i and 20,288 patients treated with GLP1RA after matching. The incidence of MALE was significantly lower in the GLP1RA group than in the SGLT2i group (3.6 vs 4.5 events per 1000 person-years; subdistribution HR 0.80; 95% CI 0.67, 0.96), primarily due to a lower incidence of critical limb ischaemia. The reduced risks of MALE associated with GLP1RA use were particularly noticeable in people with diabetic peripheral neuropathy (subdistribution HR 0.66 vs 1.11; p for interaction 0.006). CONCLUSIONS/INTERPRETATION: In people with diabetes, GLP1RA use was associated with significantly reduced risks of MALE compared with SGLT2i within the first 2 years after initiation, especially among people with diabetic neuropathy.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Lin DS, Yu AL, Lo HY, et al. Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors. Diabetologia. 2022. PMID: 35945333. doi:10.1007/s00125-022-05772-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。